TF and cancer: The second notable TF regulator, DLX1, is involved in cGMP-PKG signaling pathway, and this cyclic GMP (cGMP)/protein Kinase G (PKG) pathway has been identified as an endogenous apoptotic mechanism in a variety of cancers, notably breast and colon cancers [75], [76], [77], [78], [79].